These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 21198707)

  • 41. Considerations for the long-term treatment of chronic hepatitis B with nucleos(t)ide analogs.
    Petersen J; Buti M
    Expert Rev Gastroenterol Hepatol; 2012 Dec; 6(6):683-93; quiz 694. PubMed ID: 23237254
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Quantification of serum hepatitis B surface antigen: is it useful for the management of chronic hepatitis B?
    Janssen HL; Sonneveld MJ; Brunetto MR
    Gut; 2012 May; 61(5):641-5. PubMed ID: 22180061
    [No Abstract]   [Full Text] [Related]  

  • 43. [Protocol for the antiviral therapy of chronic hepatitis B].
    ;
    Orv Hetil; 2008 Dec; 149(49):2341-3. PubMed ID: 19042187
    [No Abstract]   [Full Text] [Related]  

  • 44. Review article: Success and failure of nucleoside and nucleotide analogues in chronic hepatitis B.
    Leemans WF; Ter Borg MJ; de Man RA
    Aliment Pharmacol Ther; 2007 Dec; 26 Suppl 2():171-82. PubMed ID: 18081660
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of 48-week pegylated interferon α-2a or nucleos(t)ide analogue therapy on renal function in Chinese patients with chronic hepatitis B.
    Zhang Y; Zhang WL; Pang XW; Wang LX; Wei X; Huang CX; Bai XF; Han S; Liu LN; Lian JQ
    Virol J; 2017 Mar; 14(1):49. PubMed ID: 28274240
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Long-term results of treatment with nucleoside and nucleotide analogues (entecavir and tenofovir) for chronic hepatitis B.
    Asselah T; Marcellin P
    Clin Liver Dis; 2013 Aug; 17(3):445-50. PubMed ID: 23905815
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Treatment has a positive impact on the long-term evolution of chronic hepatitis B].
    Marcellin P
    Gastroenterol Clin Biol; 2010 Sep; 34 Suppl 2():S99-102. PubMed ID: 21095519
    [No Abstract]   [Full Text] [Related]  

  • 48. Review article: the potential of interferon and nucleos(t)ide analogue combination therapy in chronic hepatitis B infection.
    Viganò M; Invernizzi F; Grossi G; Lampertico P
    Aliment Pharmacol Ther; 2016 Oct; 44(7):653-61. PubMed ID: 27528410
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Peginterferon Is Superior to Nucleos(t)ide Analogues for Prevention of Hepatocellular Carcinoma in Chronic Hepatitis B.
    Liang KH; Hsu CW; Chang ML; Chen YC; Lai MW; Yeh CT
    J Infect Dis; 2016 Mar; 213(6):966-74. PubMed ID: 26582959
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Impact of therapy on the outcome of chronic hepatitis B.
    Liaw YF
    Liver Int; 2013 Feb; 33 Suppl 1():111-5. PubMed ID: 23286854
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues.
    Reijnders JG; Deterding K; Petersen J; Zoulim F; Santantonio T; Buti M; van Bömmel F; Hansen BE; Wedemeyer H; Janssen HL;
    J Hepatol; 2010 Apr; 52(4):493-500. PubMed ID: 20185191
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Treatment of chronic hepatitis B infection: an update of Swedish recommendations.
    Lindh M; Uhnoo I; Bläckberg J; Duberg AS; Friman S; Fischler B; Karlström O; Norkrans G; Reichard O; Sangfeldt P; Söderström A; Sönnerborg A; Weiland O; Wejstål R; Wiström J
    Scand J Infect Dis; 2008; 40(6-7):436-50. PubMed ID: 18584530
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy of 2years of entecavir plus adefovir therapy in patients with chronic hepatitis B who had failed on prior nucleos(t)ide analog treatment.
    Wang X; Zhang C; Zhu Y; Xiong Y; Wang Y
    Antiviral Res; 2014 Mar; 103():71-7. PubMed ID: 24462954
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Low pretreatment serum HBsAg level and viral mutations as predictors of response to PEG-interferon alpha-2b therapy in chronic hepatitis B.
    Tangkijvanich P; Komolmit P; Mahachai V; Sa-nguanmoo P; Theamboonlers A; Poovorawan Y
    J Clin Virol; 2009 Oct; 46(2):117-23. PubMed ID: 19651540
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Regulatory T-cell responses in chronic hepatitis B patients treated with nucleos(t)ide analogs compared with healthy subjects and untreated infected individuals.
    Chen LY; Zhu LY; Yang BS; Bi MR; Yan BZ; Wang W; Ma YJ
    Hepatogastroenterology; 2012; 59(120):2582-6. PubMed ID: 22626879
    [TBL] [Abstract][Full Text] [Related]  

  • 56. On-treatment outcome prediction and adjustment during chronic hepatitis B therapy: now and future.
    Liaw YF
    Antivir Ther; 2009; 14(1):13-22. PubMed ID: 19320233
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Partial virological response to nucleos(t)ide analogues in naïve patients with chronic hepatitis B: From guidelines to field practice.
    Lampertico P
    J Hepatol; 2009 Apr; 50(4):644-7. PubMed ID: 19231017
    [No Abstract]   [Full Text] [Related]  

  • 58. Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy.
    Park JG; Park SY
    Clin Mol Hepatol; 2015 Sep; 21(3):242-8. PubMed ID: 26523269
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Current treatment of hepatitis B infection: where do the new nucleos(t)ide analogues fit in?].
    Fuentes Olmo J; Uribarrena Amézaga R
    Gastroenterol Hepatol; 2011; 34(7):492-503. PubMed ID: 21550145
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Long-term safety and efficacy of nucleo(t)side analogue therapy in hepatitis B.
    Buti M; Riveiro-Barciela M; Esteban R
    Liver Int; 2018 Feb; 38 Suppl 1():84-89. PubMed ID: 29427500
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.